Neisseria Meningitidis
35
1
1
32
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
23 trials with published results (66%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
2.9%
1 terminated out of 35 trials
97.0%
+10.4% vs benchmark
60%
21 trials in Phase 3/4
72%
23 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 32 completed trials
Clinical Trials (35)
Metagenomic Analysis of the Pharynx in High Risk Partners
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
Investigating Meningococcal Vaccines in Adults
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine
Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.